Back to top
more

Novavax (NVAX)

(Real Time Quote from BATS)

$8.36 USD

8.36
4,113,717

-0.20 (-2.34%)

Updated Sep 17, 2025 03:55 PM ET

After-Market: $8.39 +0.03 (0.36%) 4:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (97 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Novavax (NVAX) Q4 Earnings & Sales Miss Estimates, Stock Tanks

by Zacks Equity Research

Novavax's (NVAX) fourth-quarter earnings and revenues miss estimates. Stock tanks on moderate revenue guidance for 2024.

Zacks Equity Research

Novavax (NVAX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for Novavax (NVAX) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Novavax (NVAX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Novavax (NVAX) delivered earnings and revenue surprises of -193.88% and 12.89%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Zacks Equity Research

Novavax (NVAX) Surges 8.4%: Is This an Indication of Further Gains?

by Zacks Equity Research

Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Equity Research

Novavax (NVAX) Q4 Earnings Preview: What's in the Cards?

by Zacks Equity Research

Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Novavax's (NVAX) Updated COVID Jab Gets WHO Nod for Emergency Use

by Zacks Equity Research

Following this authorization, Novavax's (NVAX) updated COVID-19 vaccine is available as an option to all 194 WHO member states.

Zacks Equity Research

Novavax (NVAX) Beats on Q3 Earnings & Sales, Cuts Sales View

by Zacks Equity Research

Novavax (NVAX) reports better-than-expected third-quarter results, with earnings and revenues beating estimates. It lowers product sales guidance for 2023.

Zacks Equity Research

Moderna (MRNA) Down Despite Maintaining COVID Jab Sales View

by Zacks Equity Research

Though Moderna (MRNA) reiterated its sales guidance for COVID vaccine, it warned investors that it could not predict exact demand yet.

Zacks Equity Research

Novavax (NVAX) Focuses on Diversifying Vaccines Portfolio

by Zacks Equity Research

Owing to the slow uptake of Novavax's (NVAX) COVID-19 vaccine, the company is trying to develop other vaccine candidates targeting different indications.

Zacks Equity Research

The Zacks Analyst Blog Highlights Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna

by Zacks Equity Research

Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna are included in this Analyst Blog.

Zacks Equity Research

Biotech Stock Roundup: NVAX Up on Updates, ALXO Gains on Study Data & More

by Zacks Equity Research

Regulatory and pipeline updates from Novavax (NVAX) and ALX Oncology Holdings (ALXO) are in focus in the biotech sector.

Zacks Equity Research

Moderna (MRNA) to Advance COVID/Flu Combo Jab to Late-Stage Study

by Zacks Equity Research

Moderna's (MRNA) intends to start the late-stage study on its COVID-19-influenza combination vaccine candidate before year-end. A commercial launch is expected in 2025.

Zacks Equity Research

Novavax (NVAX) Up 8% on FDA Nod for Updated COVID Booster Jab

by Zacks Equity Research

Novavax's (NVAX) updated COVID vaccine is authorized under emergency use for individuals aged 12 years and older. It is currently the only non-mRNA COVID vaccine available in the country.

Zacks Equity Research

Novavax (NVAX) Soars 8.2%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Moderna (MRNA) Receives CHMP Nod for Updated COVID Vaccine

by Zacks Equity Research

Clinical data from studies on Moderna's (MRNA) updated COVID vaccine shows improved antibody responses against multiple circulating variants, including BA.2.86, EG.5 and FL.1.5.1 variants.

Zacks Equity Research

The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna and Novavax

by Zacks Equity Research

Pfizer, BioNTech, Moderna and Novavax are included in this Analyst Blog.

Kinjel Shah headshot

FDA Approves Pfizer & Moderna's New COVID Booster Vaccines

by Kinjel Shah

Pfizer (PFE)/ BioNTech (BNTX), and Moderna's (MRNA) updated mRNA vaccines are now approved for individuals 12 years of age and older and are authorized under emergency use for individuals 6 months through 11 years of age.

Zacks Equity Research

Novavax (NVAX) Up 36.8% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Moderna (MRNA) Updated COVID Jab Effective Against Pirola Variant

by Zacks Equity Research

Clinical study data shows Moderna's (MRNA) updated COVID-19 vaccine generates a robust immune response against newer circulating variants, including Pirola and Eris.

Andrew Rocco headshot

Stocks on the Mend: A Mean Reversion Duo

by Andrew Rocco

September is starting in classic, historically weak form. However, if the market finds it's footing, two stocks have explosive, reversion to the mean potential.

Zacks Equity Research

Novavax (NVAX) Stock Increases 9% in a Month: Here's Why

by Zacks Equity Research

This growth in Novavax (NVAX) is likely due to the rising COVID-19 infection cases in the United States. Management claims its updated vaccine is effective against the newly emerged virus variants.

Zacks Equity Research

Pfizer (PFE) & BioNTech Get CHMP Nod for Updated Covid-19 Jab

by Zacks Equity Research

Pfizer (PFE) and partner BioNTech receive a positive recommendation from the CHMP for its Omicron XBB.1.5-adapted Covid-19 vaccine.

Zacks Equity Research

The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics

by Zacks Equity Research

Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics are part of the Zacks top Analyst Blog.

Zacks Equity Research

Biotech Stock Roundup: REGN Up on Approval, APLS, NVAX Gain on Updates & More

by Zacks Equity Research

Regulatory updates from Regeneron (REGN) and Apellis (APLS) are in focus in the biotech sector.